1
|
Yasar B, Suh YE, Chapman E, Nicholls L, Henderson D, Jones C, Morrison K, Wells E, Henderson J, Meehan C, Sohaib A, Taylor H, Tree A, van As N. Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial. Int J Radiat Oncol Biol Phys 2024; 120:49-58. [PMID: 38499253 DOI: 10.1016/j.ijrobp.2024.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 02/20/2024] [Accepted: 03/07/2024] [Indexed: 03/20/2024]
Abstract
PURPOSE Dose-escalated radiation therapy is associated with better biochemical control at the expense of toxicity. Stereotactic body radiation therapy (SBRT) with dose escalation to the dominant intraprostatic lesion (DIL) provides a logical approach to improve outcomes in high-risk disease while limiting toxicity. This study evaluated the toxicity and quality of life (QoL) with CyberKnife-based SBRT and simultaneous integrated boost in localized prostate cancer. METHODS AND MATERIALS Eligible participants included newly diagnosed, biopsy-proven unfavorable intermediate- to high-risk localized prostate cancer (at least 1 of the following: Gleason ≥4+3, magnetic resonance imaging(MRI)-defined T3a N0, prostate-specific antigen ≥20) with up to 2 MRI-identified DILs. Participants received 36.25 Gy in 5 fractions on alternative days with a simultaneous boost to DIL up to 47.5 Gy as allowed by organ-at-risk constraints delivered by CyberKnife. All participants received androgen deprivation therapy. The primary outcome measure was acute grade 2+ genitourinary toxicity. Acute and late genitourinary and gastrointestinal toxicity using Radiation Therapy Oncology Group scoring, biochemical parameters, International Prostate Symptom Score, International Index of Erectile Function 5, and EQ-5D QoL outcomes were assessed. RESULTS Between 2013 and 2023, 20 participants were enrolled with a median follow-up of 30 months. The median D95 dose to DIL was 47.43 Gy. Cumulative acute grade 2+ genitourinary and gastrointestinal toxicity were 25% and 30%, respectively. One patient developed acute grade 3 genitourinary toxicity (5%). There is no late grade 3 genitourinary or gastrointestinal toxicity to date. International Prostate Symptom Score and urinary QoL scores recovered to baseline by 6 months. Patient-reported outcomes showed no significant change in EQ-5D QoL scores at 12 weeks and 1 year. There are no cases of biochemical relapse reported to date. CONCLUSIONS CyberKnife SBRT-delivered dose of 36.25 Gy to the prostate with a simultaneous integrated boost up to 47.5 Gy is well tolerated. Acute and late genitourinary and gastrointestinal toxicity rates are comparable to other contemporary SBRT trials and series with focal boost.
Collapse
Affiliation(s)
- Binnaz Yasar
- Royal Marsden NHS Foundation Trust, London, United Kingdom; Institute of Cancer Research, London, United Kingdom.
| | - Yae-Eun Suh
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Ewan Chapman
- St Bartholomew's Hospital, London, United Kingdom
| | | | - Daniel Henderson
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
| | - Caroline Jones
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
| | - Kirsty Morrison
- Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
| | - Emma Wells
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | | | - Carole Meehan
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Aslam Sohaib
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Helen Taylor
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Alison Tree
- Royal Marsden NHS Foundation Trust, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - Nicholas van As
- Royal Marsden NHS Foundation Trust, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| |
Collapse
|
2
|
Zhong AY, Lui AJ, Kuznetsova S, Kallis K, Conlin C, Do DD, Domingo MR, Manger R, Hua P, Karunamuni R, Kuperman J, Dale AM, Rakow-Penner R, Hahn ME, van der Heide UA, Ray X, Seibert TM. Clinical Impact of Contouring Variability for Prostate Cancer Tumor Boost. Int J Radiat Oncol Biol Phys 2024:S0360-3016(24)00740-5. [PMID: 38925224 DOI: 10.1016/j.ijrobp.2024.06.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 06/07/2024] [Accepted: 06/14/2024] [Indexed: 06/28/2024]
Abstract
PURPOSE The focal radiation therapy (RT) boost technique was shown in a phase III randomized controlled trial (RCT) to improve prostate cancer outcomes without increasing toxicity. This technique relies on the accurate delineation of prostate tumors on MRI. A recent prospective study evaluated radiation oncologists' accuracy when asked to delineate prostate tumors on MRI and demonstrated high variability in tumor contours. We sought to evaluate the impact of contour variability and inaccuracy on predicted clinical outcomes. We hypothesized that radiation oncologists' contour inaccuracies would yield meaningfully worse clinical outcomes. METHODS AND MATERIALS Forty-five radiation oncologists and 2 expert radiologists contoured prostate tumors on 30 patient cases. Of these cases, those with CT simulation or diagnostic CT available were selected for analysis. A knowledge-based planning model was developed to generate focal RT boost plans for each contour per the RCT protocol. The probability of biochemical failure (BF) was determined using a model from the RCT. The primary metric evaluated was delta BF (DBF = Participant BF - Expert BF). An absolute increase in BF ≥5% was considered clinically meaningful. RESULTS Eight patient cases and 394 target volumes for focal RT boost planning were included in this analysis. In general, participant plans were associated with worse predicted clinical outcomes compared to the expert plan, with an average absolute increase in BF of 4.3%. Of participant plans, 37% were noted to have an absolute increase in BF of 5% or more. CONCLUSIONS Radiation oncologists' attempts to contour tumor targets for focal RT boost are frequently inaccurate enough to yield meaningfully inferior clinical outcomes for patients.
Collapse
Affiliation(s)
- Allison Y Zhong
- Department of Radiation Medicine and Applied Sciences, UC San Diego School of Medicine, La Jolla, California
| | - Asona J Lui
- Department of Radiation Medicine and Applied Sciences, UC San Diego School of Medicine, La Jolla, California
| | - Svetlana Kuznetsova
- Department of Radiation Medicine and Applied Sciences, UC San Diego School of Medicine, La Jolla, California
| | - Karoline Kallis
- Department of Radiation Medicine and Applied Sciences, UC San Diego School of Medicine, La Jolla, California
| | - Christopher Conlin
- Department of Radiology, UC San Diego School of Medicine, La Jolla, California
| | - Deondre D Do
- Department of Bioengineering, UC San Diego Jacobs School of Engineering, La Jolla, California
| | - Mariluz Rojo Domingo
- Department of Bioengineering, UC San Diego Jacobs School of Engineering, La Jolla, California
| | - Ryan Manger
- Department of Radiation Medicine and Applied Sciences, UC San Diego School of Medicine, La Jolla, California
| | - Patricia Hua
- Department of Radiation Medicine and Applied Sciences, UC San Diego School of Medicine, La Jolla, California
| | - Roshan Karunamuni
- Department of Radiation Medicine and Applied Sciences, UC San Diego School of Medicine, La Jolla, California
| | - Joshua Kuperman
- Department of Radiology, UC San Diego School of Medicine, La Jolla, California
| | - Anders M Dale
- Department of Radiology, UC San Diego School of Medicine, La Jolla, California; Department of Neurosciences, UC San Diego School of Medicine, La Jolla, California; Halıcıoğlu Data Science Institute, UC San Diego School of Medicine, La Jolla, California
| | - Rebecca Rakow-Penner
- Department of Radiology, UC San Diego School of Medicine, La Jolla, California; Department of Bioengineering, UC San Diego Jacobs School of Engineering, La Jolla, California
| | - Michael E Hahn
- Department of Radiology, UC San Diego School of Medicine, La Jolla, California
| | - Uulke A van der Heide
- Department of Radiation Oncology, The Netherlands Cancer Institute (NKI-AVL), Amsterdam, The Netherlands
| | - Xenia Ray
- Department of Radiation Medicine and Applied Sciences, UC San Diego School of Medicine, La Jolla, California
| | - Tyler M Seibert
- Department of Radiation Medicine and Applied Sciences, UC San Diego School of Medicine, La Jolla, California; Department of Radiology, UC San Diego School of Medicine, La Jolla, California; Department of Bioengineering, UC San Diego Jacobs School of Engineering, La Jolla, California.
| |
Collapse
|
3
|
Jeganathan T, Salgues E, Schick U, Tissot V, Fournier G, Valéri A, Nguyen TA, Bourbonne V. Inter-Rater Variability of Prostate Lesion Segmentation on Multiparametric Prostate MRI. Biomedicines 2023; 11:3309. [PMID: 38137530 PMCID: PMC10741937 DOI: 10.3390/biomedicines11123309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2023] [Revised: 12/10/2023] [Accepted: 12/12/2023] [Indexed: 12/24/2023] Open
Abstract
INTRODUCTION External radiotherapy is a major treatment for localized prostate cancer (PCa). Dose escalation to the whole prostate gland increases biochemical relapse-free survival but also acute and late toxicities. Dose escalation to the dominant index lesion (DIL) only is of growing interest. It requires a robust delineation of the DIL. In this context, we aimed to evaluate the inter-observer variability of DIL delineation. MATERIAL AND METHODS Two junior radiologists and a senior radiation oncologist delineated DILs on 64 mpMRIs of patients with histologically confirmed PCa. For each mpMRI and each reader, eight individual DIL segmentations were delineated. These delineations were blindly performed from one another and resulted from the individual analysis of the T2, apparent diffusion coefficient (ADC), b2000, and dynamic contrast enhanced (DCE) sequences, as well as the analysis of combined sequences (T2ADC, T2ADCb2000, T2ADCDCE, and T2ADCb2000DCE). Delineation variability was assessed using the DICE coefficient, Jaccard index, Hausdorff distance measure, and mean distance to agreement. RESULTS T2, ADC, T2ADC, b2000, T2 + ADC + b2000, T2 + ADC + DCE, and T2 + ADC + b2000 + DCE sequences obtained DICE coefficients of 0.51, 0.50, 0.54, 0.52, 0.54, 0.55, 0.53, respectively, which are significantly higher than the perfusion sequence alone (0.35, p < 0.001). The analysis of other similarity metrics lead to similar results. The tumor volume and PI-RADS classification were positively correlated with the DICE scores. CONCLUSION Our study showed that the contours of prostatic lesions were more reproducible on certain sequences but confirmed the great variability of prostatic contours with a maximum DICE coefficient calculated at 0.55 (joint analysis of T2, ADC, and perfusion sequences).
Collapse
Affiliation(s)
- Thibaut Jeganathan
- Radiology Department, University Hospital, 29200 Brest, France; (T.J.); (E.S.); (V.T.)
| | - Emile Salgues
- Radiology Department, University Hospital, 29200 Brest, France; (T.J.); (E.S.); (V.T.)
| | - Ulrike Schick
- Radiation Oncology Department, University Hospital, 29200 Brest, France;
- INSERM, LaTIM UMR 1101, University of Western Brittany, 29238 Brest, France; (G.F.); (A.V.); (T.-A.N.)
| | - Valentin Tissot
- Radiology Department, University Hospital, 29200 Brest, France; (T.J.); (E.S.); (V.T.)
| | - Georges Fournier
- INSERM, LaTIM UMR 1101, University of Western Brittany, 29238 Brest, France; (G.F.); (A.V.); (T.-A.N.)
- Urology Department, University Hospital, 29200 Brest, France
| | - Antoine Valéri
- INSERM, LaTIM UMR 1101, University of Western Brittany, 29238 Brest, France; (G.F.); (A.V.); (T.-A.N.)
- Urology Department, University Hospital, 29200 Brest, France
| | - Truong-An Nguyen
- INSERM, LaTIM UMR 1101, University of Western Brittany, 29238 Brest, France; (G.F.); (A.V.); (T.-A.N.)
- Urology Department, University Hospital, 29200 Brest, France
| | - Vincent Bourbonne
- Radiation Oncology Department, University Hospital, 29200 Brest, France;
- INSERM, LaTIM UMR 1101, University of Western Brittany, 29238 Brest, France; (G.F.); (A.V.); (T.-A.N.)
| |
Collapse
|